Docetaxel
HER2-Positive Breast Cancer
Guangdong Provincial People's HospitalSmall moleculePhase 2Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 65/ 100
Competitive context
188 Active assets in the HER2-Positive Breast Cancer cohort.
View all 50 →
Same molecule, other indications
Docetaxel is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →